BioSig to Present at the 25th Annual International AF Symposium
January 21 2020 - 7:52AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company developing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that the Company will be exhibiting at the
25th Annual International AF Symposium on January 23-25, 2020 at
Gaylord National Hotel in Washington, DC.
Clinical observations collected with BioSig’s PURE EP(tm) System
will be presented by Andrea Natale, M.D., Executive Medical
Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical
Center, during Spotlight Session: Early Stage and Emerging New
Technologies and Drugs in Cardiac EP on January 23, 2020.
BioSig will be represented by its executive, clinical, marketing
and commercial teams, and will be performing product demonstrations
and hold physician sessions at the Company’s booth, as well as
feature a new product video about PURE EP(tm) System.
Previously, BioSig presented initial clinical data at Heart
Rhythm Society’s Scientific Sessions 2019, Venice Arrhythmias 2019
and 14th Annual International Symposium on Ventricular Arrhythmias:
Pathophysiology & Therapy 2019.
The PURE EP(tm) System is a computerized system intended for
acquiring, digitizing, amplifying, filtering, measuring and
calculating, displaying, recording and storing of
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP laboratory.
The PURE EP(tm) System aims to minimize noise and artifacts and
acquire high-fidelity cardiac signals. Improving fidelity of
acquired cardiac signals may potentially increase the diagnostic
value of these signals, thereby possibly improving accuracy and
efficiency of the EP studies and related procedures.
About 25th Annual International AF Symposium
This intensive, highly focused three-day symposium brings together
the world’s leading medical scientists to share in a highly
interactive environment the most recent advances in the field of
atrial fibrillation. The primary objective of the meeting is to
provide attendees with a thorough and practical course on the
current state of the art in the field of atrial fibrillation in a
scholarly and collegial atmosphere, as well as an opportunity to
network with colleagues and faculty between sessions. More
information about the event on www.afsymposium.com.
About BioSig Technologies BioSig Technologies is a
medical technology company developing a proprietary biomedical
signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our products and
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024